| Literature DB >> 27212784 |
Hong Shang1, Xiu-Li Cao1, Yu-Jie Wan2, Jin Meng3, Lu-Hong Guo1.
Abstract
UNLABELLED: This study aimed to elucidate the associations between interleukin-4 (IL-4) single nucleotide polymorphisms (SNPs), 590C/T and 589C/T, serum IL-4 levels, and atopic dermatitis (AD) in children.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27212784 PMCID: PMC4860222 DOI: 10.1155/2016/1021942
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Primer sequences of IL-4 single nucleotide polymorphisms, 590C/T and 589C/T.
| Primer sequences | |
|---|---|
| 590C/TFor | 5′-GTAAGGACCTTATGGACC-3′ |
| 590C/TRev | 5′-TACAAAGTTTCAGCATAGG-3′ |
| 589C/TFor | 5′-TAAACTTGGGAGAACATGGT-3′ |
| 589C/TRev | 5′-TGGGGAAAGATAGAGTAATA-3′ |
Severity distribution of atopic dermatitis patients with different age and gender.
| Variables | Severity of AD | ||
|---|---|---|---|
| Mild group ( | Moderate group ( | Severe group ( | |
| Age (years) | |||
| 1–5 | 7 | 25 | 13 |
| 5–10 | 6 | 16 | 6 |
| 10–12 | 2 | 5 | 2 |
| Gender | |||
| M | 7 | 16 | 3 |
| F | 8 | 30 | 18 |
Note: M, male; F, female; AD: atopic dermatitis.
Allele and genotype frequency distribution of IL-4 single nucleotide polymorphisms, 590C/T and 589C/T, in the case group and the control group.
| Case group ( | Control group ( |
| OR (95% CI) | |
|---|---|---|---|---|
| 590C/T | ||||
| CC | 3 | 6 | Ref. | |
| CT | 17 | 33 | 1.03 (0.23–4.64) | |
| TT | 62 | 61 | 0.111 | 3.03 (0.49–8.50) |
| CT + TT | 79 | 94 | 1.68 (0.41–6.94) | |
| C | 23 | 45 | Ref. | |
| T | 141 | 155 | 0.039 | 1.78 (1.03–3.09) |
| 589C/T | ||||
| CC | 1 | 3 | Ref. | |
| CT | 15 | 36 | 1.25 (0.12–13.01) | |
| TT | 66 | 61 | 0.017 | 3.25 (0.33–32.06) |
| CT + TT | 81 | 97 | 2.51 (0.256–24.56) | |
| C | 17 | 42 | Ref. | |
| T | 147 | 158 | 0.007 | 2.30 (1.25–4.22) |
Note: Ref., reference; OR, odd ratio; 95% CI, 95% confidence intervals.
The severity of AD, allele frequencies, and genotype distributions of IL-4 single nucleotide polymorphisms, 590C/T and 589C/T.
| Control group ( | Case group | |||
|---|---|---|---|---|
| Mild group ( | Moderate group ( | Severe group ( | ||
| 590C/T | ||||
| CC | 6 | 0 | 1 | 2 |
| CT | 33 | 4 | 10 | 3 |
| TT | 61 | 11 | 35 | 16 |
| C | 45 | 4 | 12 | 7 |
| T | 155 | 26 | 80 | 35 |
| 589C/T | ||||
| CC | 3 | 0 | 0 | 1 |
| CT | 36 | 7 | 7 | 1 |
| TT | 61 | 8 | 39 | 19 |
| C | 42 | 7 | 7 | 3 |
| T | 158 | 23 | 85 | 39 |
Comparison of serum IL-4 level between the case group and the control group.
| Groups |
| IL-4 (pg/mL) |
|---|---|---|
| Control group | 100 | 38.66 ± 7.99 |
| Mild group | 15 | 51.43 ± 8.94a |
| Moderate group | 46 | 86.60 ± 17.79ab |
| Severe group | 21 | 106.78 ± 26.69abc |
Note: a P < 0.05, compared with the control group; b P < 0.05, compared with the mild group; c P < 0.05, compared with the moderate group.
Effect of IL-4 single nucleotide polymorphisms, 590C/T and 589C/T, on the serum IL-4 level in the case group and the control group.
| Genotypes | Case group | Control group |
|
| |
|---|---|---|---|---|---|
| 590C/T | CC | 37.27 ± 9.12 | 36.41 ± 7.32 | 0.154 | 0.882 |
| CT | 74.11 ± 19.28a | 37.90 ± 6.26 | 7.545 | 0.000 | |
| TT | 90.82 ± 25.12ab | 39.30 ± 4.16 | 15.930 | 0.000 | |
|
| |||||
| 589C/T | CC | 89.26 | 34.02 ± 6.43 | — | — |
| CT | 55.31 ± 15.82 | 36.52 ± 8.71 | 4.334 | 0.000 | |
| TT | 91.59 ± 24.26b | 40.16 ± 7.37 | 16.420 | 0.000 | |
Note: a P < 0.05, compared with wild homozygotes; b P < 0.05, compared with heterozygote.
Association of the severity of AD with serum IL-4 level of IL-4 single nucleotide polymorphisms, 590C/T and 589C/T.
| Genotypes | Control group | Mild group ( | Moderate group ( | Severe group ( | |
|---|---|---|---|---|---|
| 590C/T | CC | 36.4 ± 7.3 | — | 37.2 | 37.3 ± 12.9 |
| CT | 37.9 ± 6.2 | 49.3 ± 10.6a | 77.2 ± 12.0ab | 96.6 ± 9.9abcde | |
| TT | 39.3 ± 8.9 | 52.2 ± 8.7a | 90.7 ± 16.3abe | 117.4 ± 13.1abcde | |
|
| |||||
| 589C/T | CC | 22.11 ± 2.6 | — | — | 89.26 |
| CT | 31.52 ± 3.07 | 42.85 ± 2.88a | 61.04 ± 10.72ab | 95.53 | |
| TT | 43.69 ± 5.44 | 58.06 ± 6.71ae | 91.19 ± 14.65abe | 108.30 ± 27.66abc | |
Note: a P < 0.05, compared with the control group; b P < 0.05, compared with the mild group; c P < 0.05, compared with the moderate group; d P < 0.05, compared with the wild homozygote; e P < 0.05, compared with the heterozygote.